Table 2 Patient baseline characteristics
| Â | Â | Â | CK | EBRT |
|---|---|---|---|---|
# Evaluable patients | Â | Â | Â | |
| Â | Total | Â | 43 | 75 |
# Follow up from end of RT | Â | Â | ||
| Â | Â | Thru Year 1 | 43 | 42 |
| Â | Â | Thru Year 2 | 38 | 62 |
| Â | Â | Thru Year 3 | 27 | 68 |
# with PSA follow-up for all 3 intervals | 26 | 37 | ||
Median age at RT (yrs) (range) | 69.0 (51 – 83) | 69.8 (55 – 82) | ||
Gleason score: | Â | Â | Â | Â |
|  | 3 + 3 |  | 24 (56%) | 59 (79%) |
|  | 3 + 4 |  | 19 (44%) | 16 (21%) |
Pretreatment PSA (ng/mL) | Â | Â | Â | |
|  | Median (range) | 6.2 (2.0 – 13.5) | 5.9 (0.1 – 16.7) | |
| Â | # >10.0Â ng/mL | 10 (23%) | 19 (25%) | |
Years of RT |  |  | 2006 – 2011 | 1997 – 2006 |
Median follow-up (mos.) (range) | 29.3 (12 – 75) | 62.1 (15 – 156) | ||